BridgeBio Oncology Therapeutics (BBOT), a company advancing small molecule therapeutics targeting RAS and PI3Ka malignancies, ...

BridgeBio Oncology has entered a definitive merger agreement with Helix Acquisition Corp II, which will result in the ...

For a while, special purpose acquisition companies were biotech’s hot ticket to the public markets. | For a while, special ...

The deal comes amid an uptick in so-called SPAC deals, which had fallen out of favor due to poor returns and increased ...

BridgeBio Oncology Therapeutics, which was spun out of BridgeBio Pharma (NASDAQ:BBIO) last year, has agreed to merge with ...

Prescription totals for Attruby, which is locked in a closely watched commercial battle with Pfizer’s tafamidis, have more ...

But the direct-to-consumer ad didn't come from Palo Alto-based Bridge Bio (Nasdaq: BBIO); instead it was produced by Pfizer ...

BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its price target lifted by Citigroup from $45.00 to $49.00 in a research ...

BofA raised the firm’s price target on BridgeBio (BBIO) to $46 from $45 and keeps a Buy rating on the shares after accounting for the updated ...

Feb. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today the pricing of $500 million aggregate principal amount of 1 ...

Long term debt management strategy will strengthen the balance sheet without increasing total liabilities - Refinancing term ...

Scotiabank analyst Greg Harrison maintained a Hold rating on Apellis Pharmaceuticals (APLS – Research Report) today and set a price target of ...